Who
Amit Hasija
CFO & EVP of Corp. Development
Company insider
Files Form 4 as: CFO & EVP of Corp. Development, Milestone Pharmaceuticals.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $316K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Sep 2019
- Last trade
- 2 Feb 2026
- Last filed
- 5 Feb 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 5 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 2 Feb 2026filed 5 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —136,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —136,000 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —20,100 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,100 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $24K12,245 at $1.93 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,100 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —20,100 | filing |
| 26 Jan 2026filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $24K12,245 at $1.93 | filing |
| 15 Dec 2025filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $135K58,007 at $2.32 | filing |
| 15 Dec 2025filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $135K58,007 at $2.32 | filing |
| 12 Dec 2025filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 12 Dec 2025filed 28 Jan 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Dec 2025filed 28 Jan 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Dec 2025filed 28 Jan 2026 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 | filing |
News
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology ConferencesMIST · manilatimes.net · 19 Oct 2026Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY)MIST · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Amit Hasija; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.